Household Net Worth, Racial Disparities, and Hormonal Therapy Adherence Among Women With Early-Stage Breast Cancer
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Purpose: Nonadherence to adjuvant hormonal therapy is common and is associated with increased prescription copayment amount and black race. Studies suggest that household wealth may partly explain racial disparities. We investigated the impact of net worth on disparities in adherence and discontinuation. Patients and Methods: We used the OptumInsight insurance claims database to identify women older than age 50 years diagnosed with early breast cancer, from January 1, 2007, to December 31, 2011, who were using hormonal therapy. Nonadherence was defined as a medication possession ratio of ≤ 80% of eligible days over a 2-year period. We evaluated the association of demographic and clinical characteristics, annual household income, household net worth (< $250,000, $250,000 to $750,000, or > $750,000), insurance type, and copayments (< $10, $10 to $20, or > $20) with adherence to hormonal therapy. Logistic regression analyses were conducted by sequentially adding sociodemographic and financial variables to race. Results: We identified 10,302 patients; 2,473 (24%) were nonadherent. In the unadjusted analyses, adherence was negatively associated with black race (odds ratio [OR], 0.76; P < .001), advanced age, comorbidity, and Medicare insurance. Adherence was positively associated with medium (OR, 1.33; P < .001) and high (OR, 1.66; P < .001) compared with low net worth. The negative association of black race with adherence (OR, 0.76) was reduced by adding net worth to the model (OR, 0.84; P < .05). Correcting for other variables had a minimal impact on the association between race and adherence (OR, 0.87; P = .08). The interaction between net worth and race was significant (P < .01). Conclusion: We found that net worth partially explains racial disparities in hormonal therapy adherence. These results suggest that economic factors may contribute to disparities in the quality of care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945
Ramsey, S., Blough, D., Kirchhoff, A., Kreizenbeck, K., Fedorenko, C., Snell, K., Newcomb, P., Hollingworth, W., & Overstreet, K. (2013) · Health Affairs · doi:10.1377/hlthaff.2012.1263 · Cited by 699
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Patient adherence and persistence with oral anticancer treatment
Ruddy, K., Mayer, E., & Partridge, A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20004 · Cited by 569 · cited 1×
“This issue will become increasingly important as more oral antineoplastic drugs come into use.(48) The average total monthly cost of oral biologic therapies ranges from $5,000 to $8,000, whereas AIs cost between $180 and $400 per month.”
BackgroundMcCowan, C., Shearer, J., Donnan, P. T., Dewar, J. A., Crilly, M., Thompson, A. M., & Fahey, T. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604758 · Cited by 343
Darkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725060-00004 · Cited by 271
Weaver, K. E., Rowland, J. H., Bellizzi, K. M., & Aziz, N. M. (2010) · Cancer · doi:10.1002/cncr.25209 · Cited by 254 · cited 1×
“Survivors of cancer who report financial problems are also more likely to report delaying medical care or foregoing medical care and prescriptions.(35,36) It is not surprising that patients who are more financially vulnerable are more likely to discontinue therapy early or delay renewing prescriptions.”
BackgroundAdherence to endocrine therapy for breast cancer
Chlebowski, R. T., & Geller, M. L. (2006) · Oncology · doi:10.1159/000100444 · Cited by 251
Conn, V. S., Hafdahl, A. R., Cooper, P. S., Ruppar, T. M., Mehr, D. R., & Russell, C. L. (2009) · The Gerontologist · doi:10.1093/geront/gnp037 · Cited by 227
Adjuvant hormonal therapy use among insured, low-income women with breast cancer
Kimmick, G., Anderson, R., Camacho, F., Bhosle, M., Hwang, W., & Balkrishnan, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2419 · Cited by 198
Mortality Impact of Less-than-Standard Therapy in Older Breast Cancer Patients
Yood, M. U., Owusu, C., Buist, D. S. M., Geiger, A. M., Field, T. S., Thwin, S. S., Lash, T. L., Prout, M. N., Wei, F., Quinn, V. P., et al. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.07.015 · Cited by 155
A review of interventions used to improve adherence to medication in older people
Banning, M. (2009) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2009.03.011 · Cited by 98
Cited by
Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival
Jemal, A., Ward, E. M., Johnson, C. J., Cronin, K. A., Ma, J., Ryerson, A. B., Mariotto, A., Lake, A. J., Wilson, R., Sherman, R. L., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx030 · Cited by 1,556
Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer
Chavez-MacGregor, M., Clarke, C. A., Lichtensztajn, D. Y., & Giordano, S. H. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3856 · Cited by 370
Maraka, S., Mwangi, R., McCoy, R. G., Yao, X., Sangaralingham, L. R., Singh Ospina, N. M., O’Keeffe, D. T., De Ycaza, A. E. E., Rodriguez-Gutierrez, R., Coddington, C. C., et al. (2017) · BMJ · doi:10.1136/bmj.i6865 · Cited by 249
Jemal, A., Robbins, A. S., Lin, C. C., Flanders, W. D., DeSantis, C. E., Ward, E. M., & Freedman, R. A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7932 · Cited by 181
Shi, Y., Hunter Guevara, L. R., Dykhoff, H. J., Sangaralingham, L. R., Phelan, S., Zaccariello, M. J., & Warner, D. O. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.0321 · Cited by 158
Metadata
- Authors
- Hershman, D. L., Tsui, J., Wright, J. D., Coromilas, E. J., Tsai, W. Y., & Neugut, A. I.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-03-20
- Volume
- 33
- Issue
- 9
- Pages
- 1053-1059
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102823761
- Cited by
- 122
- References
- 12
- FWCI
- 18.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.